Questions & explanations
1. A startup has invented a new medical device. Should they use a distribution partner or sell directly to hospitals? Why?
They should likely use a distribution partner because hospitals often trust established medical equipment distributors. Distributors already have relationships with hospital purchasing departments and understand the regulations. Selling directly would require the startup to build a sales team and gain trust from scratch, which is slow and expensive. The distributor can also handle logistics, training, and service. However, the startup will have less control and lower profit margins. They should choose a distributor with experience in medical devices and a good reputation. This approach speeds up market access.
2. What does patent harmonization mean?
Patent harmonization means making patent laws and procedures more similar across different countries. The goal is to reduce the cost and complexity of getting patents worldwide. For example, harmonization could mean that all countries use the same rules for what is patentable. It could also mean that patent applications are examined in a similar way. This would help inventors who want protection in many countries. International treaties like the PCT and TRIPS are steps toward harmonization. However, full harmonization is difficult because countries have different legal systems and interests.
3. What are the three main ways a startup can exit, and how do they differ?
The three main exit strategies are acquisition, IPO, and SPAC. In an acquisition, a larger company buys the startup, giving founders and investors cash or stock. An IPO (initial public offering) means selling shares to the public on a stock exchange, which often provides more liquidity but requires regulatory filings. A SPAC (special purpose acquisition company) is a shell company that merges with the startup to take it public faster, with less regulatory scrutiny. Acquisitions are usually quicker and less risky, while IPOs and SPACs can offer higher valuations but more complexity and cost.
4. What role do international agreements like TRIPS play in developing countries' patent laws?
The TRIPS agreement (Trade-Related Aspects of Intellectual Property Rights) sets minimum standards for patent protection that all World Trade Organization members must follow. Developing countries had to change their laws to meet these standards, for example, by granting patents for 20 years. However, TRIPS also includes flexibilities like compulsory licensing and exceptions for public health. Many developing countries have used these flexibilities to adapt patent laws to their needs. The agreement has pushed countries to strengthen patent protection, but with room for local adjustments.
5. How can a company manage conflict between its direct sales channel and its distribution partners?
Conflict can happen when both channels try to sell to the same customer. To manage it, the company can clearly define which customers each channel serves. For example, direct sales might handle large accounts, while distributors handle small ones. They can also set different prices or product versions for each channel. Communication is key: the company should explain the rules to both sides and listen to concerns. Sometimes they create a partner program that rewards distributors for referring customers to direct sales. The goal is to make all channels feel valued and avoid competition.
6. Compare the purpose of patent term extension for drugs versus for other inventions.
Patent term extension is mainly used for drugs because they face long regulatory delays. Other inventions, like a new type of battery, usually do not need such approval. For drugs, the extension compensates for time lost in clinical trials and FDA review. For other inventions, the patent term is usually enough because they can be sold quickly. However, some agricultural products also get extensions for similar reasons. The purpose is to ensure that inventors have enough market exclusivity to profit from their work. Without extensions, drug companies might not invest in new medicines.
7. Compare confirmation bias and availability heuristic. How are they similar and different?
Both are cognitive biases that distort thinking. Confirmation bias makes you favor information that confirms your beliefs, while availability heuristic makes you rely on easily recalled examples. They are similar because both lead to flawed judgments without you realizing. They differ in what causes the error: confirmation bias is about seeking or interpreting evidence, while availability heuristic is about memory ease. For an entrepreneur, confirmation bias might make them ignore market data, and availability heuristic might make them overestimate demand based on a few stories.
8. What are some challenges to achieving global patent harmonization?
Countries have different legal traditions, economic interests, and levels of development. For example, some countries want strong patent protection to encourage innovation, while others want flexibility to provide affordable medicines. There are disagreements on what should be patentable, such as software or living organisms. National patent offices also have different examination standards and fee structures. Political and cultural differences make it hard to agree on common rules. Despite these challenges, efforts like the Patent Law Treaty (PLT) aim to simplify formalities.
9. How can a company accelerate the adoption of a new product? Give two strategies.
A company can accelerate adoption by making the product easy to try and by showing its benefits clearly. One strategy is to offer free trials or samples so people can experience the product without risk. Another is to use testimonials from early adopters to build trust. They can also partner with influencers who recommend the product to their followers. Reducing the price temporarily can also encourage trial. Finally, making the product compatible with existing habits helps people adopt it faster. All these strategies reduce the perceived risk and increase the perceived value.
10. What is the doctrine of equivalents?
The doctrine of equivalents is a legal rule that stops someone from copying an invention by making small changes. Even if a product does not use the exact words of a patent claim, it can still be considered infringement if it does the same job in the same way. For example, if a patent says 'nail' and someone uses a screw, a court might find it equivalent. This rule helps protect inventors from obvious tricks. However, it also creates uncertainty because it is not always clear what counts as equivalent. Courts look at whether the change is truly different or just a substitute.
11. Give an example of a situation where prosecution history estoppel would apply.
Suppose an inventor applies for a patent on a 'device that uses electricity'. The patent office rejects it because such a broad claim already exists. The inventor then changes the claim to 'device that uses batteries'. Later, a competitor makes a device that uses solar power. The inventor tries to sue under the doctrine of equivalents, saying solar is equivalent to batteries. But prosecution history estoppel applies because the inventor gave up other power sources. The court would likely say the inventor cannot claim solar power. The inventor is stuck with the narrower claim.
12. How does a company decide whether to develop a technology internally or license it from outside?
The company compares the cost, time, and risk of internal development versus licensing. If the technology is complex and the company has strong R&D, internal development might be better for long-term advantage. But if the technology is already available and the company needs it quickly, licensing is faster. Also, if the company lacks expertise, licensing avoids failure. The company also considers intellectual property protection—if licensing gives weak rights, internal development may be safer. Finally, strategic fit matters: core technologies are often developed internally.